StockData
Castle Biosciences Inc logo

Castle Biosciences Inc (CSTL) stock

CSTLNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 11/307% below fair value
$32.86−0.55 (-1.63%)

Close on Nov 20, 2026Market cap $1.00BP/E –Yield 0.00%

Castle Biosciences free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Castle Biosciences's free cash flow for the twelve months ending Sep 30, 2026 was $3.96M, down 84.4% year over year. For fiscal 2025 it was $28.33M, down 22.5% from the year before. The highest annual figure on record is $36.54M in fiscal 2024.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$28.33M-22.5%
FY2024Dec 31, 2024$36.54M–
FY2023Dec 31, 2023-$19.25M–
FY2022Dec 31, 2022-$47.29M–
FY2021Dec 31, 2021-$22.47M-539.3%
FY2020Dec 31, 2020$5.11M-15.9%
FY2019Dec 31, 2019$6.08M–
FY2018Dec 31, 2018-$12.57M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$12.25M+57.1%
Q2 FY2026Jun 30, 2026$6.55M-43.3%
Q1 FY2026Mar 31, 2026-$34.58M–
Q4 FY2025Dec 31, 2025$19.75M+17.6%
Q3 FY2025Sep 30, 2025$7.80M-54.0%
Q2 FY2025Jun 30, 2025$11.56M-38.4%
Q1 FY2025Mar 31, 2025-$10.78M–
Q4 FY2024Dec 31, 2024$16.80M+13.5%
Q3 FY2024Sep 30, 2024$16.96M+563.3%
Q2 FY2024Jun 30, 2024$18.77M–
Q1 FY2024Mar 31, 2024-$15.99M–
Q4 FY2023Dec 31, 2023$14.79M–
Q3 FY2023Sep 30, 2023$2.56M–
Q2 FY2023Jun 30, 2023-$7.82M–
Q1 FY2023Mar 31, 2023-$28.78M–
Q4 FY2022Dec 31, 2022-$7.79M–
Q3 FY2022Sep 30, 2022-$7.26M–
Q2 FY2022Jun 30, 2022-$10.41M–
Q1 FY2022Mar 31, 2022-$21.83M–
Q4 FY2021Dec 31, 2021-$3.67M–
Q3 FY2021Sep 30, 2021-$7.06M–
Q2 FY2021Jun 30, 2021-$7.35M-162.6%
Q1 FY2021Mar 31, 2021-$4.38M–
Q4 FY2020Dec 31, 2020-$1.02M-124.6%
Q3 FY2020Sep 30, 2020-$4.86M-929.5%
Q2 FY2020Jun 30, 2020$11.75M+3789.1%
Q1 FY2020Mar 31, 2020-$751.00K-171.9%
Q4 FY2019Dec 31, 2019$4.15M–
Q3 FY2019Sep 30, 2019$586.00K–
Q2 FY2019Jun 30, 2019$302.00K–
Q1 FY2019Mar 31, 2019$1.04M–
Q4 FY2018Dec 31, 2018-$3.22M–
Q3 FY2018Sep 30, 2018-$1.97M–

More Castle Biosciences figures

See a number that looks wrong?